STUDY ON TARGETING OF LUNG CANCER WITH POLYPEPTIDE RGD

Authors

  • Jieke Tang Department of Anesthesiology, First Affiliated Hospital of Jinan University, Guangzhou, China
  • Zhao Zhong 1 Department of Anesthesiology, First Affiliated Hospital of Jinan University, Guangzhou, China 2 Guangzhou First People’s Hospital, the Second Affiliated Hospital of South China University of Technology, Guangzhou, China
  • Fangchao Chen Guangzhou First People’s Hospital, the Second Affiliated Hospital of South China University of Technology, Guangzhou, China
  • Jinyong Liu Guangzhou First People’s Hospital, the Second Affiliated Hospital of South China University of Technology, Guangzhou, China

Keywords:

Lung Cancer, Polypeptide, arginine-glycine-aspartic acid

Abstract

In this study, we aimed to study the selectivity of therapeutic targets in cancer chemotherapy through a new targeting peptide. Peptide specifically binding to human lung adenocarcinoma was identified through a NCI-H1299 subcutaneous xenograft model, results showed that RGD was concentrated mainly in the tumor while less accumulation of fluorescence in the tumor was found in control group animals. Ability of RGD to target human lung cancer tissue in vitro was investigated through tissue microarray, results show that a 7-fold higher detection rate of [RGD] FITC was achieved compared with the control group, indicating the potential of RGD as carriers for targeted cancer therapy drug. In conclusion, RGD is specifically targeted to human lung adenocarcinoma xenografted and had high specifically and affinity with lung cancer tissues, it might be an efficient method to increase the selectivity of therapeutic targets in cancer chemotherapy.

References

Downloads

Published

2018-03-22

Issue

Vol. 1 No. 1 (2018)

Section

Research Article

How to Cite

Jieke Tang, Zhao Zhong, Fangchao Chen, Jinyong Liu. Study On Targeting Of Lung Cancer With Polypeptide Rgd. Acta Translational Medicine. 2018, 1(1): 13-18.